GLP-1 medications explained simply: they are a class of injectable drugs that mimic a natural gut hormone to control appetite and blood sugar. Semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro) are the best-known examples, and at Nusbaum Medical Centers in Cedar Knolls, NJ, we prescribe and monitor them as part of a complete medical weight-loss plan — not a quick fix.
- On this page:
- How They Work
- Who Qualifies for GLP-1 Medications
- What to Expect During Treatment
- Safety, Side Effects and Regulatory Oversight
- Realistic Results and Long-Term Planning
- Common Myths About GLP-1 Medications
- FAQs
How GLP-1 Medications Work
To understand GLP-1 medications explained in plain terms, start with the hormone they mimic. GLP-1, or glucagon-like peptide-1, is released naturally in the gut after eating. It slows how quickly food leaves the stomach, tells the brain you are full, and helps the pancreas release the right amount of insulin. GLP-1 medications amplify and extend that signal, which is why appetite and portion sizes often shrink noticeably within the first few weeks of treatment.
Semaglutide vs. Tirzepatide
Semaglutide acts on the GLP-1 receptor alone. Tirzepatide adds a second hormone pathway, GIP, which for many patients produces somewhat greater weight loss and blood sugar improvement. We help patients weigh semaglutide against tirzepatide based on their history and goals.
Who Qualifies for GLP-1 Medications
Candidacy typically depends on body mass index and the presence of weight-related health conditions such as type 2 diabetes, high blood pressure, sleep apnea or fatty liver disease, though every case is individualized. A physician consultation should always include a review of your full medical history, current medications and any personal or family history of thyroid or pancreatic conditions, since these can affect eligibility.
At our medically supervised weight-loss injection program in Cedar Knolls, we do not prescribe based on a questionnaire alone. Labs, a physical evaluation and an honest conversation about goals come first.
What to Expect During Treatment
Most GLP-1 medications are started at a low dose and increased gradually over weeks to months, which is the single best strategy for minimizing nausea, constipation or other gastrointestinal side effects. Appetite reduction is often noticeable within the first two weeks, while more significant weight loss builds over several months.
- Weekly or twice-monthly self-injections, depending on the medication
- Regular check-ins to review side effects and progress
- Nutrition guidance to protect muscle mass during rapid weight loss
- Periodic labs to monitor blood sugar and other markers
Patients following a structured medical weight-loss program tend to see steadier, more sustainable results than those self-managing dosing without oversight.
Safety, Side Effects and Regulatory Oversight
GLP-1 medications carry a well-documented side-effect profile, mostly gastrointestinal, along with a boxed warning regarding a theoretical thyroid tumor risk seen in rodent studies; they are not recommended for people with a personal or family history of medullary thyroid carcinoma. The U.S. Food and Drug Administration continues to monitor these medications closely as their use has expanded, and periodic guidance updates are part of why ongoing physician supervision matters more than a one-time prescription.
Compounded, unregulated versions of these medications have circulated outside licensed pharmacies; we only prescribe FDA-approved formulations dispensed through licensed pharmacies.
Realistic Results and Long-Term Planning
Clinical trial data suggests average weight loss in the range of 10–22% of body weight depending on the specific medication and duration of use, though individual results vary considerably. Because obesity is a chronic condition, most patients need an ongoing maintenance plan rather than a fixed treatment window. We discuss this openly during consultations so expectations are realistic from day one.
For patients whose weight or health history makes surgery a better fit, we also cover how these medications compare to weight-loss surgery and to newer procedures in our guide to bariatric surgery vs. GLP-1 medications.
Common Myths About GLP-1 Medications
With GLP-1 medications explained so widely — and inconsistently — online, several myths tend to persist. The first is that they are only for people with diabetes; while GLP-1 medications were first developed for type 2 diabetes, several are now FDA-approved specifically for chronic weight management in patients without diabetes. Another common myth is that they are a “quick fix” that requires no other effort; in reality, patients who pair treatment with nutrition changes and physical activity see better, more durable results than those relying on the medication alone.
A third myth is that all GLP-1 medications are essentially interchangeable. In practice, semaglutide and tirzepatide differ in mechanism, average results and side-effect profile, and compounded, non-FDA-approved versions sold outside licensed pharmacies carry meaningfully different safety and quality assurances than the approved products we prescribe. Finally, some patients assume that once side effects appear, the medication is simply “not for them” — but in our experience, most gastrointestinal side effects respond well to slower titration and dose adjustment rather than requiring patients to stop treatment altogether.
Understanding GLP-1 medications explained also means knowing how to evaluate where you get them. Telehealth companies advertising rapid-fire prescriptions without labs, a real medical history, or ongoing follow-up have become common, and they carry real risk — from incorrect dosing to missing a contraindication that a thorough evaluation would have caught. A responsible prescriber reviews your full history, checks relevant labs, titrates slowly, and stays available for follow-up as your dose changes or side effects appear. If a provider will not do all of these things, that is a signal to look elsewhere, regardless of how convenient the process seems.
It is equally important to understand who should not use GLP-1 medications. They are generally not recommended during pregnancy or while trying to conceive, and are contraindicated for anyone with a personal or family history of medullary thyroid carcinoma or MEN 2 syndrome. Patients with a history of pancreatitis, severe gastrointestinal disease, or gastroparesis should discuss these conditions carefully with their physician before starting treatment, since GLP-1 medications can worsen delayed gastric emptying. A thorough intake conversation at the start of care is designed specifically to catch these situations before a prescription is ever written.
